Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

ARS Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, JULY 23, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. ("ARS" OR THE "COMPANY") (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. - SPRY

NEW YORK, JULY 21, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. (ARS OR THE COMPANY) (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK, JULY 16, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. ("ARS" OR THE "COMPANY") (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JULY 14, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. (ARS OR THE COMPANY) (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK, JULY 9, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. ("ARS" OR THE "COMPANY") (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JULY 07, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. (ARS OR THE COMPANY) (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

RICHARD LOWENTHAL, CHIEF EXECUTIVE OFFICER, TRANSITIONING FOLLOWING MORE THAN A DECADE OF LEADERSHIP SINCE CO-FOUNDING THE COMPANY

ARS PHARMACEUTICALS ANNOUNCES CEO SUCCESSION

NEW YORK--(BUSINESS WIRE)--SHAREHOLDERS WHO HELD ARS PHARMACEUTICALS (NASDAQ: SPRY) STOCK WATCHED THE VALUE DROP MORE THAN 23% IN AFTER-HOURS TRADING ON JUNE 24, 2026, AFTER THE COMPANY DISCLOSED THAT NEFFY RECEIVED NO NEW COMMERCIAL FORMULARY ADDITIONS OR PAYER-COVERAGE DECISIONS IN THE JULY 1, 2026 REVIEW CYCLE. INVESTORS WHO LOST MONEY ON SPRY ARE ENCOURAGED TO SUBMIT THEIR INFORMATION TO DISCUSS THEIR LEGAL RIGHTS. YOU MAY ALSO CONTACT JOSEPH E. LEVI, ESQ. VIA EMAIL AT JLEVI@LEVIKORSINSKY.

SPRY INVESTOR ALERT: LEVI & KORSINSKY INVESTIGATES ARS PHARMACEUTICALS (SPRY) FOR POTENTIAL SECURITIES FRAUD

NEW YORK, JUNE 30, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ARS PHARMACEUTICALS, INC. (ARS OR THE COMPANY) (NASDAQ: SPRY). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NO NEW COMMERCIAL FORMULARY ADDITIONS OR COVERAGE DECISIONS ISSUED FOR NEFFY (EPINEPHRINE NASAL SPRAY) IN THE JULY 1, 2026 CYCLE; COMPANY TO CONTINUE PAYER DISCUSSIONS FOR POTENTIAL FUTURE INCLUSION

ARS Pharmaceuticals, Inc.

SPRY

Price

Financial Reports

No items found.

Press Releases

ARS Pharmaceuticals, Inc.

SPRY.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SPRY